Provided by Tiger Fintech (Singapore) Pte. Ltd.

AtriCure

31.40
-0.2100-0.66%
Post-market: 31.400.00000.00%17:02 EDT
Volume:494.65K
Turnover:15.56M
Market Cap:1.55B
PE:-38.77
High:31.94
Open:31.94
Low:31.13
Close:31.61
Loading ...

Press Release: AtriCure to Announce First Quarter 2025 Financial Results

Dow Jones
·
08 Apr

Trump Tariffs Will Sow Long-term Structural Dislocation, Oppenheimer Says

MT Newswires Live
·
08 Apr

Is AtriCure (NASDAQ:ATRC) A Risky Investment?

Simply Wall St.
·
05 Apr

AtriCure Price Target Maintained With a $60.00/Share by Citizens Capital Markets

Dow Jones
·
02 Apr

Canaccord Genuity Adjusts Price Target on AtriCure to $52 From $66, Maintains Buy Rating

MT Newswires Live
·
28 Mar

AtriCure Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
28 Mar

AtriCure price target lowered to $52 from $66 at Canaccord

TIPRANKS
·
28 Mar

AtriCure Is Maintained at Overweight by JP Morgan

Dow Jones
·
27 Mar

AtriCure Price Target Maintained With a $51.00/Share by Needham

Dow Jones
·
27 Mar

AtriCure price target raised to $58 from $57 at BTIG

TIPRANKS
·
27 Mar

AtriCure Highlights Growth and Innovation at Investor Day

TIPRANKS
·
27 Mar

AtriCure Price Target Maintained With a $51.00/Share by Needham

Dow Jones
·
21 Mar

Analysts Offer Insights on Healthcare Companies: Atricure (ATRC) and Neumora Therapeutics, Inc. (NMRA)

TIPRANKS
·
18 Feb

BRIEF-Atricure Files For Mixed Shelf; Size Not Disclosed - SEC Filing

Reuters
·
15 Feb

AtriCure files automatic mixed securities shelf

TIPRANKS
·
15 Feb

AtriCure Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.
·
14 Feb

AtriCure’s Earnings Call Highlights Strong Growth and Positive Outlook

TIPRANKS
·
14 Feb

AtriCure (ATRC) Upgraded to Buy: Here's What You Should Know

Zacks
·
14 Feb

Oppenheimer Adjusts AtriCure Price Target to $45 From $36, Maintains Outperform Rating

MT Newswires Live
·
13 Feb

Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year?

Zacks
·
13 Feb